ACURX PHARMACEUTICALS, INC.

Analyst Reco. Acurx Pharmaceuticals, Inc.

Equities

ACXP

US00510M1045

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
2.31 ^USD	+0.43%		+12.14%	-39.69%

May. 15	Acurx Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C. difficile Infection	CI
May. 15	Transcript : Acurx Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 15, 2024

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

H.C. Wainwright Adjusts Price Target on Acurx Pharmaceuticals to $12 From $14, Keeps Buy Rating	Mar. 19	MT
HC Wainwright Adjusts Price Target on Acurx Pharmaceuticals to $14 From $13, Keeps Buy Rating	Dec. 15	MT
Maxim Raises Price Target on Acurx Pharmaceuticals to $10 From $7, Keeps Buy Rating	23-10-11	MT
HC Wainwright Adjusts Price Target on Acurx Pharmaceuticals to $13 From $14, Keeps Buy Rating	23-08-15	MT
HC Wainwright Initiates Acurx Pharmaceuticals With Buy Rating, Sets $14 Price Target	22-12-19	MT
Alliance Global Starts Acurx Pharmaceuticals at Buy With $14 Price Target	22-10-20	MT
Maxim Group Starts Acurx Pharmaceuticals at Buy With $12 Price Target	21-11-29	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Secure my Investments

fermer